EXHIBIT 99.1 MiNK Reports First Quarter 2024 Results NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune- mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the r ...

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical- stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. "This quarter w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 (St ...

Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediat ...

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 14, 2024. MiNK executives will host a conference call and webcast ...

MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today ann ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40908 MiNK Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Securities registered pursuant to Section 12(b) ...

Financial Data and Key Metrics Changes - The net loss for the year ended December 31, 2023, was $22.5 million or $0.65 per share, compared to a net loss of $28 million or $0.83 per share for the same period in 2022 [65] - Cash used in operations for the three and twelve months ended December 31, 2023, was $3 million and $15.8 million respectively, compared to $4.4 million and $18.9 million for the same periods in 2022 [90] Business Line Data and Key Metrics Changes - The company has achieved significant milestones in advancing its allogeneic iNKT cell programs, with nearly 100 patients treated to date, showcasing efficacy in solid tumor cancers and immune-related diseases [8][11] - The flagship program, agenT-797, is now advancing to a Phase 2 trial in second-line gastric cancer, with promising outcomes observed in refractory solid tumor cancers [11][15] Market Data and Key Metrics Changes - The company is well-positioned in the therapeutic area of cell therapies, particularly in oncology and pulmonary diseases, with a focus on addressing unmet medical needs [17][37] - The demand for treatments in respiratory distress is increasing, with over 600,000 individuals affected annually in the US alone [36][118] Company Strategy and Development Direction - The company aims to revolutionize treatment access to effective cell therapies, focusing on the development of its lead program, agenT-797, and exploring therapeutic areas with rapid development pathways [29][37] - Collaborations remain a core strategy, with ongoing discussions for strategic partnerships and project-based financing to support clinical programs [64][73] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of iNKT cells to make a meaningful difference in patient outcomes, particularly in oncology and respiratory distress [37][118] - The company is committed to financial prudence while expanding its clinical data set and exploring new therapeutic areas [48][96] Other Important Information - The company has developed an FDA-cleared end-to-end automated manufacturing process for iNKT cells, enhancing its internal manufacturing capacity [22][38] - The collaboration with Immunoscape aims to leverage T cell receptor platforms and proprietary targets for novel therapeutic developments [28][59] Q&A Session Summary Question: Can you provide details on the Phase 2 gastric study and patient enrollment? - Management confirmed that there are no gaps in patient enrollment, and the demand for the trial is high, with expectations to conclude enrollment in the first half of the year [77][80] Question: What are the strategies for bringing additional capital into the company? - Strategies include strategic collaborations, regional partnerships, and expanding interactions with project-based financing and investors [71][73] Question: What is the status of engineered iNKT cell efforts in autoimmune diseases? - The company is actively pursuing trials in graft versus host disease and exploring the potential of iNKT cells in metabolic-related disorders [122][124]

MiNK Therapeutics Fourth Quarter and Year-End 2023 Results [Overview and Strategic Highlights](index=1&type=section&id=Overview%20and%20Strategic%20Highlights) MiNK Therapeutics advanced its iNKT cell programs in 2023, progressing agenT-797 to Phase 2 for gastroesophageal cancers and forming a key research partnership for TCR-based therapies - The company primarily focuses on advancing its lead program, **agenT-797**, in indications with promising proof-of-concept data[3](index=3&type=chunk) - A Phase 2 study of **agenT-797** for gastroesophageal cancers has been initiated, with initial data expected later in the year[3](index=3&type=chunk)[7](index=7&type=chunk) - A research collaboration with ImmunoScape was established to accelerate the development of **TCR-based therapies** for solid tumors[3](index=3&type=chunk)[6](index=6&type=chunk) [Clinical Program Updates](index=1&type=section&id=Clinical%20Program%20Updates) MiNK advanced agenT-797 to Phase 2 for gastroesophageal cancers, showed high survival in ARDS, and progressed MiNK-215 with preclinical efficacy in NSCLC [AgenT-797 in Solid Tumors](index=1&type=section&id=AgenT-797%20in%20Solid%20Tumors) A Phase 2 investigator-sponsored trial for **agenT-797** in second-line gastroesophageal cancers is actively enrolling patients, evaluating a combination therapy regimen - A Phase 2 trial (NCT06251973) for second-line gastroesophageal cancers has launched and is actively enrolling patients[7](index=7&type=chunk)[8](index=8&type=chunk) - The trial is led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center and supported by Stand Up To Cancer[8](index=8&type=chunk) - The combination therapy includes **agenT-797**, Agenus' **botensilimab** (CTLA-4), **balstilimab** (anti-PD-1), ramucirumab, and paclitaxel[8](index=8&type=chunk) [AgenT-797 in Acute Respiratory Distress Syndrome (ARDS)](index=1&type=section&id=AgenT-797%20in%20Acute%20Respiratory%20Distress%20Syndrome%20(ARDS)) A Phase 1/2 study of **agenT-797** in ARDS demonstrated high survival rates and reduced secondary infections, with plans for further advancement in viral ARDS - A Phase 1/2 study published in Nature Communications demonstrated clinical activity in severe acute respiratory distress[7](index=7&type=chunk)[8](index=8&type=chunk) - Survival rates exceeded **70%** for patients on mechanical ventilation and over **80%** for those on VV ECMO, significantly higher than the **10%** control group survival[8](index=8&type=chunk) - **AgenT-797** treatment led to an over **80% decrease** in secondary bacterial and fungal infections in the highest dose cohort[8](index=8&type=chunk) [Research and Preclinical Programs](index=1&type=section&id=Research%20and%20Preclinical%20Programs) MiNK is expanding its early-stage pipeline via a collaboration with Immunoscape for TCR-based therapies and advancing preclinical candidate **MiNK-215** for NSCLC with IND-enabling activities underway - The collaboration with Immunoscape aims to accelerate **TCR-based therapies** development against novel targets in T cells and iNKT cells for solid tumors[6](index=6&type=chunk)[9](index=9&type=chunk) - Preclinical efficacy data for **MiNK-215** presented at ASGCT 2023 showed activity in NSCLC models[17](index=17&type=chunk) - IND-enabling activities and supportive financing discussions for **MiNK-215** are currently underway[17](index=17&type=chunk) [Manufacturing Progress](index=2&type=section&id=Manufacturing%20Progress) MiNK Therapeutics maintains internal, FDA-cleared, automated, and closed-system manufacturing for its allogeneic iNKT cells, supplying ongoing clinical trials - The company continued internal manufacturing of its **allogeneic iNKT cells** to supply ongoing clinical trials[10](index=10&type=chunk) - The manufacturing process is **FDA-cleared**, **automated**, and utilizes a **closed-system**[10](index=10&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) MiNK ended 2023 with **$3.4 million** cash, secured an additional **$5 million** post-year-end, and reduced its full-year net loss to **$22.5 million** due to decreased R&D spending and improved operational efficiency [Key Financial Position (Balance Sheet)](index=2&type=section&id=Key%20Financial%20Position%20(Balance%20Sheet)) As of December 31, 2023, MiNK's cash and cash equivalents were **$3.4 million**, a significant decrease from **$19.6 million** in 2022, with total assets also declining, though **$5 million** was received post-year-end via a convertible note - Ended 2023 with a cash balance of **$3.4 million** and received an additional **$5 million** after year-end under a convertible note agreement with Agenus Inc[11](index=11&type=chunk) Balance Sheet Summary (in thousands USD) | | December 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $3,367 | $19,636 | | Total assets | $4,552 | $21,472 | | Total stockholders' equity (deficit) | $(18,055) | $(401) | [Statement of Operations](index=3&type=section&id=Statement%20of%20Operations) For full year 2023, MiNK reported a net loss of **$22.5 million** (**$0.65 per share**), an improvement from **$28.0 million** in 2022, primarily due to decreased R&D expenses from **$23.1 million** to **$15.5 million** Statement of Operations Summary (in thousands USD, except per share data) | | Year ended Dec 31, 2023 | Year ended Dec 31, 2022 | | :--- | :--- | :--- | | Research and development | $15,490 | $23,115 | | General and administrative | $7,431 | $7,834 | | **Operating loss** | **$22,921** | **$30,949** | | **Net loss** | **$22,458** | **$27,991** | | **Net loss per share** | **$0.65** | **$0.83** | [Cash Flow](index=2&type=section&id=Cash%20Flow) MiNK demonstrated improved cash management, with cash used in operations decreasing to **$15.8 million** for full year 2023 from **$18.9 million** in 2022, and **$3.0 million** for Q4 2023 from **$4.4 million** in Q4 2022 Cash Used in Operations (in thousands USD) | Period | 2023 | 2022 | | :--- | :--- | :--- | | Q4 | $3,025 | $4,431 | | Full Year | $15,752 | $18,867 |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-40908 MiNK Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2142067 ...